AcelRx Pharma rises as analyst starts at "Buy"

by admin on April 8, 2013

Shares of AcelRx Pharmaceuticals Inc. edged higher Monday after a Jefferies & Co. analyst said he thinks the company's pain treatment system will be approved, and U.S. sales will reach $400 million a year. …

View full post on pain – Yahoo! News Search Results

Previous post:

Next post: